CHF555.20 Lonza Group AG (LONN.SW, SIX) intraday before Jan 28 earnings: key metrics to watch
We are watching Lonza Group AG (LONN.SW) intraday at CHF555.20 as the company heads into an earnings release on 28 January 2026. The focus keyword LONN.SW stock matters because valuation and volume have started moving ahead of the print. Price is down 0.39% intraday on volume 139,650, slightly above the 30-day average, suggesting traders are positioning for guidance and margin updates.
Earnings calendar and near-term catalysts for LONN.SW stock
Lonza reports results on 28 Jan 2026; investors should expect revenue detail across Biologics, Small Molecules and Cell & Gene. The upcoming print is the primary intraday catalyst for LONN.SW stock and will likely move shares if management updates guidance or capital allocation priorities.
Analyst commentary ahead of the date often focuses on margin trajectory and order backlog. We note the company quietly traded between CHF564.40 intraday high and CHF555.20 low today, signalling mixed conviction ahead of results.
Price, volume and trading context for LONN.SW stock
Current price is CHF555.20 with a change of -2.20 from the previous close of CHF557.40. Volume is 139,650, above average 136,413, and relative volume is 1.02 which reflects intraday positioning ahead of earnings.
Technicals show RSI 51.12 and ADX 25.79, indicating a steady market structure rather than extreme momentum. The 50-day average price is CHF541.11 and the 200-day average is CHF555.08, so the stock sits essentially at its long-term moving average.
Valuation and fundamental metrics in the earnings spotlight for LONN.SW stock
Lonza trades at a trailing PE of 53.49 with EPS 10.38 and market cap CHF38,944,809,915.00, implying premium valuation versus Swiss healthcare peers. Price-to-sales is 5.49 and price-to-book is 4.52, underscoring investor expectations for durable growth.
Cash flow metrics show operating cash flow per share 16.59 but negative free cash flow per share -3.80, a point management will need to address in the earnings call. Debt-to-equity is 0.54 and interest coverage is 7.20, which supports the company’s investment plans but constrains near-term margin flexibility.
Sector comparison and market backdrop for LONN.SW stock
Lonza sits in the Swiss Healthcare sector, which shows YTD strength and a one-year return of 8.03% for the sector. The sector average PE is 34.40, so LONN.SW stock trades at a premium to peers given its contract-manufacturing growth prospects in biologics and cell & gene.
Sector flows matter here: a stronger healthcare tape ahead of major clinical readouts could lift Lonza, while broader SMI weakness can pressure even stocks with solid order books. See market context in Barron’s SMI overview.
Meyka AI rating and forecast for LONN.SW stock
Meyka AI rates LONN.SW with a score out of 100: the model gives a score 67.98 (Grade B) with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a near-term monthly price of CHF597.66 and a one-year level of CHF484.49. Compared with the current price CHF555.20, the monthly forecast implies +7.65% upside and the one-year forecast implies -12.74% downside. Forecasts are model-based projections and not guarantees.
Risks and what to watch in the LONN.SW stock earnings report
Key downside risks include weaker-than-expected Biologics bookings, margin pressure from capex, and slower ramp of cell and gene capacity. Lonza’s free cash flow is negative per share -3.80, which increases sensitivity to working capital swings.
On the upside, strong CMC wins or improved guidance for long-term contract manufacturing could justify a premium valuation. Watch management commentary on capital spending and contract backlog, and listen for updates on capsule and small-molecule demand.
Final Thoughts
Key takeaways for LONN.SW stock on 23 Jan 2026: Lonza trades at CHF555.20 intraday with slightly elevated volume as the market positions ahead of the 28 Jan 2026 earnings release. Valuation metrics are rich—PE 53.49, P/S 5.49, P/B 4.52—so investors need confirmation from revenue growth or margin improvement to support the premium. Meyka AI’s model projects CHF597.66 over the next month, implying +7.65% upside from today’s price, but a one-year model point at CHF484.49 implies -12.74% downside. We emphasise the forecasts are model-based projections and not guarantees. For intraday traders the immediate move will hinge on guidance and order updates; for longer-term holders, monitor capex, free cash flow recovery, and contract wins. Meyka AI provides this as an AI-powered market analysis platform; these grades and forecasts are informational only and not investment advice.
FAQs
When does Lonza report earnings and why does it matter for LONN.SW stock?
Lonza reports on 28 Jan 2026. The print matters because guidance on Biologics, Cell & Gene ramps, and capital spending will drive short-term volatility in LONN.SW stock and influence medium-term valuation.
What valuation should investors monitor for LONN.SW stock?
Focus on trailing PE 53.49, price-to-sales 5.49, and free cash flow per share -3.80. Improvement in FCF and margin guidance would be the clearest justification for the premium valuation of LONN.SW stock.
How does the sector backdrop affect LONN.SW stock before earnings?
Swiss healthcare is outperforming broader markets; sector PE averages 34.40. Strong sector flows can help LONN.SW stock, but Lonza must show growth and margin visibility to keep its premium multiple.
What are the most important numbers to watch on the earnings call for LONN.SW stock?
Watch bookings, revenue by division, operating margin guidance, capex outlook, and free cash flow trajectory. Any update that narrows uncertainty could move LONN.SW stock materially.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
